Bioactive Lipid Mediators in Cardiopulmonary Pharmacology, Volume 97 updates readers on topics surrounding Bioactive lipid mediators. These mediators are involved in a vast array of signaling pathways that regulate both physiological and pathophysiological responses. Chapters in this new release include Cyclooxygenases and Vascular Function, Cyclooxygenases and Platelet Function, Eicosanoids and Cardiomyopathies, Cytochrome P450 Bioactive Lipids in the Heart, Epoxide Hydrolase and Leukotoxin in the Heart and Lung, Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response, Bioactive Lipids in Hypertension, Cytochrome P450 Metabolites and Angiogenesis, 20-Hydroxyeicosatetraenoic Acid and Vascular Function, and more.
Other critical sections cover Cytochrome P450 Eicosanoids and the Brain, Omega-3 Oxylipids, Resolvins, Lipoxins and Inflammation, Endocannabinoids as Bioactive Metabolites, and Oxylipins and Aspirin Exacerbated Respiratory Disease.
1. 1 Introduction - p. 41 2. 2 Role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide in the modulation of adenosine-induced vascular response in mice - p. 59 3. 3 Modulation of adenosine-induced vascular response and the role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide hydrolase in high salt-diet-fed mice - p. 58 4. 4 Modulation of coronary reactive hyperemia and the role of adenosine A2A receptor, CYP450-epoxygenase, soluble epoxide hydrolase, ω-hydroxylase, cyclooxygenase, lipoxygenase, and PPAR-γ in mice - p. 79 5. 5 Role of plasma/isolated heart perfusate oxylipins in the modulation of coronary reactive hyperemia in mice and cardiovascular diseases - p. 96 6. 6 Clinical trials of soluble epoxide hydrolase inhibitors and adenosine receptors agonists - p. 95 7. 7 Conclusion - p. 104 8. References - p. 103 9. Chapter Three: Cyclooxygenases and platelet functions - p. 133 10. Chapter Four: The roles of eicosanoids in myocardial diseases - p. 167 11. Chapter Five: Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs - p. 201 12. Chapter Six: 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond - p. 229 13. Chapter Seven: Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease - p. 257 14. Chapter Eight: Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation - p. 304 15. Chapter Nine: Lipid mediators generated by the cytochrome P450—Epoxide hydrolase pathway - p. 327 16. Chapter Ten: Role of omega-3 and omega-6 endocannabinoids in cardiopulmonary pharmacology - p. 391 17. Chapter Eleven: The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD) - p. 423
Bioactive Lipid Mediators in Cardiopulmonary Pharmacology, Volume 97 updates readers on topics surrounding Bioactive lipid mediators. These mediators are involved in a vast array of signaling pathways that regulate both physiological and pathophysiological responses. Chapters in this new release include Cyclooxygenases and Vascular Function, Cyclooxygenases and Platelet Function, Eicosanoids and Cardiomyopathies, Cytochrome P450 Bioactive Lipids in the Heart, Epoxide Hydrolase and Leukotoxin in the Heart and Lung, Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response, Bioactive Lipids in Hypertension, Cytochrome P450 Metabolites and Angiogenesis, 20-Hydroxyeicosatetraenoic Acid and Vascular Function, and more.
Other critical sections cover Cytochrome P450 Eicosanoids and the Brain, Omega-3 Oxylipids, Resolvins, Lipoxins and Inflammation, Endocannabinoids as Bioactive Metabolites, and Oxylipins and Aspirin Exacerbated Respiratory Disease.
1. 1 Introduction - p. 41 2. 2 Role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide in the modulation of adenosine-induced vascular response in mice - p. 59 3. 3 Modulation of adenosine-induced vascular response and the role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide hydrolase in high salt-diet-fed mice - p. 58 4. 4 Modulation of coronary reactive hyperemia and the role of adenosine A2A receptor, CYP450-epoxygenase, soluble epoxide hydrolase, ω-hydroxylase, cyclooxygenase, lipoxygenase, and PPAR-γ in mice - p. 79 5. 5 Role of plasma/isolated heart perfusate oxylipins in the modulation of coronary reactive hyperemia in mice and cardiovascular diseases - p. 96 6. 6 Clinical trials of soluble epoxide hydrolase inhibitors and adenosine receptors agonists - p. 95 7. 7 Conclusion - p. 104 8. References - p. 103 9. Chapter Three: Cyclooxygenases and platelet functions - p. 133 10. Chapter Four: The roles of eicosanoids in myocardial diseases - p. 167 11. Chapter Five: Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs - p. 201 12. Chapter Six: 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond - p. 229 13. Chapter Seven: Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease - p. 257 14. Chapter Eight: Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation - p. 304 15. Chapter Nine: Lipid mediators generated by the cytochrome P450—Epoxide hydrolase pathway - p. 327 16. Chapter Ten: Role of omega-3 and omega-6 endocannabinoids in cardiopulmonary pharmacology - p. 391 17. Chapter Eleven: The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD) - p. 423
